Skip to content
Clinical Trials – home
CzechiaBack to Czechia

Clinical trials in Usti Nad Labem – page 35

1 086 clinical trials in Usti Nad Labem, Czechia across 2 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

CzechiaOur site in CzechiaKlinickeTesty.cz(opens in a new tab)
Usti Nad Labem at a glance
1 086
clinical trials
  • Research sites2
Type of trial
Recruitment status
Quick filters

1 086 trials in Usti Nad Labem

Open in trial search

Lichen planopilaris

Not yet recruiting

Safety and Efficacy of Oral Brepocitinib in Adults with Lichen Planopilaris: A Randomized, Double‑Blind, Placebo‑Controlled Phase 2/3 Study

Investigational
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years
  • Substances:Brepocitinib Tosilate
  • Sponsor:Priovant Therapeutics Inc.

Dermatitis atopic

Not yet recruiting

Efficacy and Safety of Rezpegaldesleukin (NKTR-358) in Patients Aged 12 Years and Older with Moderate-to-Severe Atopic Dermatitis

Investigational
Countries:CzechiaCzechia
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Rezpegaldesleukin
  • Sponsor:Nektar Therapeutics

Dermatitis atopic

Not yet recruiting

Efficacy and Safety of Rezpegaldesleukin (NKTR-358) in Patients Aged ≥12 Years with Moderate-to-Severe Atopic Dermatitis

Investigational
Countries:CzechiaCzechia
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Rezpegaldesleukin
  • Sponsor:Nektar Therapeutics

Ovarian cancer

Not yet recruiting

Study of gsk5733584 with bevacizumab versus standard drug combination in patients with platinum-sensitive ovarian cancer

Registered drugNo placebo
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab
  • Sponsor:Glaxosmithkline Research & Development Limited

Systemic scleroderma+2

Not yet recruiting

Long‑term Safety and Tolerability of Anifrolumab in Adults with Systemic Lupus Erythematosus Who Completed Prior Study

Registered drugNo placebo
Countries:CzechiaCzechia
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Anifrolumab
  • Sponsor:AstraZeneca AB

Efficacy and Safety of REGN7508, REGN9933, and Rivaroxaban in Adults with Peripheral Artery Disease after Recent Lower‑Extremity Revascularization

Registered drug
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years
  • Substances:REGN9933
  • Sponsor:Regeneron Pharmaceuticals Inc.

Systemic lupus erythematosus+1

Not yet recruiting

Randomized Placebo‑Controlled Trial of Cenerimod for Efficacy and Safety in Adults with Systemic Lupus Erythematosus and Active Lupus Nephritis

Investigational
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years
  • Substances:Cenerimod
  • Sponsor:Viatris Innovation GmbH

Petosemtamab versus cetuximab plus drug combination as first‑line treatment for adults with metastatic left‑sided colorectal cancer

Registered drugNo placebo
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years
  • Substances:Calcium Folinate
  • Sponsor:Genmab A/S

Cardiovascular disorder+3

Not yet recruiting

Study of Once‑Weekly Eloralintide (LY3841136 Sodium) in Adults with Obesity or Overweight, Type 2 Diabetes, and High Cardiovascular Risk

Investigational
Countries:CzechiaCzechia
  • Participants:18–64 years
  • Substances:LY3841136 sodium
  • Sponsor:Eli Lilly & Co.

Obesity+1

Not yet recruiting

Phase 3 Double‑Blind Study of Olatorepatide for Weight Loss in Adults with Overweight or Obesity Without Diabetes

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Olatorepatide
  • Sponsor:Regeneron Pharmaceuticals Inc.

Atrial fibrillation

Not yet recruiting

Stroke and Systemic Embolism Prevention with REGN7508 and REGN9933 in Adults with Atrial Fibrillation Unsuitable for Oral Anticoagulation (Phase 3)

Investigational
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years
  • Substances:REGN9933
  • Sponsor:Regeneron Pharmaceuticals Inc.

Atrial fibrillation

Not yet recruiting

Prevention of Stroke and Systemic Embolism in Atrial Fibrillation Patients Treated with REGN7508 (cenvacibart) versus Apixaban

Registered drug
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years
  • Substances:Apixaban
  • Sponsor:Regeneron Pharmaceuticals Inc.

Other cities in Czechia

The busiest research cities in the country

All 150 cities in Czechia

Clinical research in Usti Nad Labem

What the registry says about research in the country

01 Cardiovascular Research

Innovative trials focusing on cardiovascular disease management and prevention, including studies on hypertrophic cardiomyopathy and treatments for acute myocardial infarction.

  • Heart failure treatments
  • Stroke prevention
  • Deep vein thrombosis therapy

Several studies are evaluating novel compounds to reduce cardiovascular events and improve patient outcomes.

02 Gastrointestinal Studies

Multiple clinical investigations targeting Crohn's Disease, with research focusing on innovative therapies and treatment combinations for moderate to severe cases.

  • Inflammatory bowel disease management
  • Novel therapeutic approaches
  • Long-term disease control

Research aims to improve quality of life for patients with chronic gastrointestinal conditions.

03 Metabolic Disorders

Comprehensive research into diabetes management and hypertriglyceridemia, including specialized treatments for both Type 1 and Type 2 diabetes in various age groups.

  • Blood sugar control
  • Lipid management
  • Pediatric diabetes care

Studies focus on developing targeted therapies for better metabolic control.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.